Application of High-Throughput Flow Cytometry in Early Drug Discovery: An AstraZeneca Perspective

被引：12

作者：

Ding, Mei ^{[1
]}

Clark, Roger ^{[2
]}

Bardelle, Catherine ^{[3
]}

Backmark, Anna ^{[1
]}

Norris, Tyrrell ^{[1
]}

Williams, Wendy ^{[4
]}

Wigglesworth, Mark ^{[3
]}

Howes, Rob ^{[1
]}

机构：

[1] AstraZeneca, IMED Biotech Unit, Discovery Sci, Gothenburg, Sweden

[2] AstraZeneca, IMED Biotech Unit, Discovery Sci, Milton Rd, Cambridge CB4 0WG, England

[3] AstraZeneca, IMED Biotech Unit, Discovery Sci, Macclesfield, Cheshire, England

[4] Antibody Discovery & Prot Engn, Cambridge, England

来源：

SLAS DISCOVERY | 2018年 / 23卷 / 07期

关键词：

high-throughput flow cytometry; drug discovery; multiplex; HTS; AstraZeneca; LYTIC GRANULE EXOCYTOSIS; SCREENING PLATFORM; PATIENT SAMPLES; MULTIPLEX ASSAY; IDENTIFICATION; PRINCIPLES; PROFILES; TOXICITY; ENABLES; CELLS;

D O I：

10.1177/2472555218775074

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

Flow cytometry is a powerful tool providing multiparametric analysis of single cells or particles. The introduction of faster plate-based sampling technologies on flow cytometers has transformed the technology into one that has become attractive for higher throughput drug discovery screening. This article describes AstraZeneca's perspectives on the deployment and application of high-throughput flow cytometry (HTFC) platforms for small-molecule high-throughput screening (HTS), structure-activity relationship (SAR) and phenotypic screening, and antibody screening. We describe the overarching HTFC workflow, including the associated automation and data analysis, along with a high-level overview of our HTFC assay portfolio. We go on to discuss the practical challenges encountered and solutions adopted in the course of our deployment of HTFC, as well as future enhancements and expansion of the technology to new areas of drug discovery.

引用

页码：719 / 731

页数：13

共 50 条

[41] Accelerating drug discovery by high-throughput combinatorial synthesis
Banville, SC
Zuckermann, RN
PROCEEDINGS OF THE INTERNATIONAL SYMPOSIUM ON LABORATORY AUTOMATION AND ROBOTICS 1996, 1997, : 77 - 92
[42] High-Throughput crystallographic fragment screening for drug discovery
Metz, Alexander
Huschinann, Franziska
Schiebel, Johannes
Mueller, Utiye
Weiss, Manfred
Heine, Andreas
Melte, Gerhard
ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2018, 74 : E24 - E24
[43] High-Throughput Transcriptome Profiling in Drug and Biomarker Discovery
Yang, Xiaonan
Kui, Ling
Tang, Min
Li, Dawei
Wei, Kunhua
Chen, Wei
Miao, Jianhua
Dong, Yang
FRONTIERS IN GENETICS, 2020, 11
[44] High-throughput kinase profiling as a platform for drug discovery
David M. Goldstein
Nathanael S. Gray
Patrick P. Zarrinkar
Nature Reviews Drug Discovery, 2008, 7 : 391 - 397
[45] High-throughput screening approaches to TB drug discovery
Stanley, Sarah A.
Grant, Sarah S.
Barczak, Amy K.
Hung, Deborah T.
TUBERCULOSIS, 2013, 93 (01) : 110 - 110
[46] Modern analytical approaches to high-throughput drug discovery
Gomez-Hens, A.
Aguilar-Caballos, M. P.
TRAC-TRENDS IN ANALYTICAL CHEMISTRY, 2007, 26 (03) : 171 - 182
[47] High-throughput crystallography for lead discovery in drug design
Blundell, TL
Jhoti, H
Abell, C
NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (01) : 45 - 54
[48] High-throughput crystallization and structure determination in drug discovery
Stewart, L
Clark, R
Behnke, C
DRUG DISCOVERY TODAY, 2002, 7 (03) : 187 - 196
[49] High-throughput crystallography for lead discovery in drug design
Tom L. Blundell
Harren Jhoti
Chris Abell
Nature Reviews Drug Discovery, 2002, 1 : 45 - 54
[50] High-throughput virtual screening for drug discovery in parallel
Toledo-Sherman, LM
Chen, DQ
CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, 2002, 5 (03) : 414 - 421

← 1 2 3 4 5 →